HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder Companies’ Post-Pandemic Struggle Continues In Q3; Travel Retail Down 45%

Executive Summary

Lauder lowers its fiscal 2023 full-year sales guidance a third time as travel retail recovery in Asia lags and global travel retail sales plunge 45% organically. On the bright side, the rest of the firm’s business grew 10%.

You may also be interested in...



Inter Parfums Expects ‘Another Spectacular Year’ As Prestige Fragrance Boom Continues

The New York-based firm recorded 24% growth in fiscal 2023 first-quarter net sales to $311.7m. The performance reflects growth across all regions as consumers continue to splurge on more expensive fragrances in larger sizes, a trend that arose at the height of the global pandemic.

Lauder Q2 Sales Pummeled By China Closures, US Skin-Care Slowdown

The Estee Lauder Companies, Inc. reported a 17% decline in fiscal 2023 second quarter sales due to pandemic-related closures in China as well as a slowdown in orders of US skin-care products. But the company says both its Chinese and US markets should be “growth drivers” in the second half of the year as markets open up and new innovations kick in.

Estee Lauder Makes Tom Ford Beauty Entirely Its Own In Deal Valued At $2.8Bn

Estee Lauder’s agreement values Tom Ford Beauty and its trademarks at $2.8bn. Acquisition will “fortify" growth plans for the brand and help to fuel long-term luxury beauty momentum, says CEO Fabrizio Freda.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel